JD
Therapeutic Areas
Dialectic Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| DT2216 | Fibrolamellar Carcinoma | Phase 1/2 |
Leadership Team at Dialectic Therapeutics
JS
Joshua Sills
Chief Operating Officer
SF
Stephen Friedberg
Chief Financial Officer
LT
Larry Tremaine, PhD
Chief Scientific Officer
JS
James Strauss, MD
Chief Medical Officer
GZ
Guangrong Zheng, PhD
Director of Medicinal Chemistry & Scientific Co-founder